Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 5:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Collagenase Clear all
Completed Phase 2 Interventional Results available

Safety and Effectiveness of EN3835 in the Treatment of EFP in Women

NCT03329989
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy, Cellulite
Interventions
Collagenase Clostridium Histolyticum
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
11
States / cities
Scottsdale, Arizona • Huntington Beach, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2020 · Synced Sep 17, 2026, 5:36 PM EDT
Completed Phase 1 Interventional

The Safety, Effectiveness, and Pharmacokinetics of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)

NCT01518907
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy, Cellulite
Interventions
COLLAGENASE CLOSTRIDIUM HISTOLYTICUM
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
21 Years to 60 Years · Female only
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Sep 17, 2026, 5:36 PM EDT
Active, not recruiting Phase 4 Interventional

Delayed Dose Collagenase Clostridium Histolyticum (CCH) Protocol for Men With Peyronie's Disease

NCT06649539
View directory record Official record
Conditions
Peyronie Disease
Interventions
Collagenase Clostridium Histolyticum, RestoreX, Sildenafil
Drug · Device
Lead sponsor
Charitable Union for the Research and Education of Peyronie's Disease
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Orem, Utah
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 17, 2026, 5:36 PM EDT
Completed Phase 4 Interventional

Efficacy of a Novel CCH Protocol for PD Among Prior Non-responders

NCT05108558
View directory record Official record
Conditions
Peyronie's Disease
Interventions
CCH administration, Control - Crossover to CCH, RestoreX
Drug · Device
Lead sponsor
Charitable Union for the Research and Education of Peyronie's Disease
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Orem, Utah
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 17, 2026, 5:36 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Double Blind Study to Evaluate the Efficacy of Collagenase Histolyticum in the Treatment of Lipoma

NCT02249052
View directory record Official record
Conditions
Lipoma
Interventions
AA4500, placebo
Drug
Lead sponsor
Gerut, Zachary, M.D.
Individual
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
2
States / cities
Hewlett, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Sep 17, 2026, 5:36 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Effect of Concentrating Endogenous Stromal Cells in the Fat Graft

NCT01564524
View directory record Official record
Conditions
Facial Injuries, Adipose Tissue
Interventions
Fat graft surgical procedure
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 110 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 24, 2016 · Synced Sep 17, 2026, 5:36 PM EDT
Not yet recruiting Phase 2 Interventional

Clinical Study to Evaluate the Safety and the Efficacy of EscharEx Drug Product (EX-03 Formulation) and Its Placebo Compared to Collagenase, Non-surgical Standard of Care, in Patients With Venous Leg Ulcers

NCT06690177
View directory record Official record
Conditions
Venus Leg Ulcers
Interventions
EscharEx (EX-03), Placebo (Gel vehicle)
Drug
Lead sponsor
MediWound Ltd
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Carlsbad, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Sep 17, 2026, 5:36 PM EDT
Not yet recruiting No phase listed Observational

Collagenase Biobank Study

NCT07211230
View directory record Official record
Conditions
Colorectal (Colon or Rectal) Cancer
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 17, 2026, 5:36 PM EDT
Completed Phase 2 Interventional Results available

Clostridium Histolyticum Collagenase Injection for Urethral Disease

NCT02948842
View directory record Official record
Conditions
Urethral Stricture
Interventions
Clostridium Histolyticum Collagenase, Saline
Drug · Other
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Sep 17, 2026, 5:36 PM EDT
Completed Phase 2 Interventional

A Study to Assess Collagenase Clostridium Histolyticum (CCH) in the Treatment of Plantar Fasciitis (PFA)

NCT06169319
View directory record Official record
Conditions
Plantar Fasciitis
Interventions
Collagenase Clostridium Histolyticum (CCH), Placebo
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
39
States / cities
Tucson, Arizona • Castro Valley, California • Corona, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 17, 2026, 5:36 PM EDT
Completed Phase 4 Interventional Results available

A Study to Look at the Effects of Four Weeks of Treatment on the Healing of Diabetic Foot Ulcers

NCT01143714
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
Santyl, White Petrolatum
Drug · Other
Lead sponsor
Healthpoint
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
6
States / cities
Sylmar, California • Chicago, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated May 5, 2013 · Synced Sep 17, 2026, 5:36 PM EDT
Completed Phase 3 Interventional Results available

A Study of AA4500 in Men With Peyronie's Disease

NCT01243411
View directory record Official record
Conditions
Peyronie's Disease
Interventions
AA4500
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
13
States / cities
Burbank, California • Middlebury, Connecticut • New Haven, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Sep 17, 2026, 5:36 PM EDT
Completed Phase 4 Interventional Results available

Enzymatic Versus (vs) Autolytic Debridement of Diabetic Foot Ulcers

NCT01143727
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
Santyl, Tegaderm Hydrogel
Drug
Lead sponsor
Healthpoint
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Sep 17, 2026, 5:36 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease

NCT00528840
View directory record Official record
Conditions
Advanced Dupuytren's Disease
Interventions
collagenase clostridium histolyticum
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
14
States / cities
Phoenix, Arizona • Tucson, Arizona • Burbank, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2017 · Synced Sep 17, 2026, 5:36 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Ultrasound B Mode Imaging and Elastography

NCT04607187
View directory record Official record
Conditions
Dupuytren's Contractures
Interventions
Not listed
Lead sponsor
Theresa Bass-Goldman
Other
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Wheaton, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Sep 17, 2026, 5:36 PM EDT
Not yet recruiting Not applicable Interventional

Autologous Fat Grafting for the Treatment of Chronic Tendinopathy

NCT07748793
View directory record Official record
Conditions
Chronic Tendinopathy
Interventions
Micro-Fragmented Adipose Tissue (MFAT) injection
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 17, 2026, 5:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics of a Single Dose of CCH (3.36 mg) in Subjects With EFP

NCT03675685
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy
Interventions
CCH (collagenase clostridium histolyticum)
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Sep 17, 2026, 5:36 PM EDT
Completed Phase 1 Interventional

EZCast-DFU Study With Portal for Application of Topical Medications

NCT02131961
View directory record Official record
Conditions
Foot Ulcer, Diabetic Foot
Interventions
Collagenase ointment, Modified Contact Cast System
Drug · Device
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 9, 2015 · Synced Sep 17, 2026, 5:36 PM EDT
Completed No phase listed Observational

Longterm Observational Study in Subjects Treated With AA4500 in AUX-CC-854, 856, 857, 858 & 859

NCT00954746
View directory record Official record
Conditions
Dupuytren's Disease
Interventions
Not listed
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
645 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
23
States / cities
Phoenix, Arizona • Tucson, Arizona • Burbank, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2015 · Synced Sep 17, 2026, 5:36 PM EDT
Not listed Early Phase 1 Interventional

Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection

NCT04326036
View directory record Official record
Conditions
Pulmonary Alveolar Proteinosis, COPD, Idiopathic Pulmonary Fibrosis, Viral Pneumonia, Coronavirus Infection, Interstitial Lung Disease
Interventions
Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF), Centricyte 1000, IV Deployment Of cSVF In Sterile Normal Saline IV Solution, Liberase Enzyme (Roche), Sterile Normal Saline for Intravenous Use
Procedure · Device · Drug
Lead sponsor
Black Tie Medical, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Stevensville, Montana
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Sep 17, 2026, 5:36 PM EDT
Completed Phase 2 Interventional Results available

AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder

NCT01483963
View directory record Official record
Conditions
Adhesive Capsulitis, Frozen Shoulder
Interventions
AA4500 0.29 mg/1 mL, AA4500 0.58 mg/2 mL, AA4500 0.58 mg/1 mL, AA4500 0.58 mg/0.5 mL, Shoulder exercises
Biological · Other
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Sep 17, 2026, 5:36 PM EDT
Completed Phase 4 Interventional Results available

Wound Edge Changes Following Treatment With Santyl

NCT01197898
View directory record Official record
Conditions
Diabetic Foot Ulcers, Diabetic Foot Wounds
Interventions
Collagenase Santyl Ointment, Placebo Comparator
Biological · Other
Lead sponsor
Healthpoint
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Sep 17, 2026, 5:36 PM EDT
Terminated Phase 4 Interventional Results available

Study of SANTYL® vs Hydrogel (SoloSite®) for Pressure Ulcers

NCT02718625
View directory record Official record
Conditions
Pressure Ulcer
Interventions
Santyl, SoloSite®
Biological
Lead sponsor
Smith & Nephew, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Lee's Summit, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Sep 17, 2026, 5:36 PM EDT
Completed Phase 4 Interventional Results available

Santyl vs. Sharp Debridement of Diabetic Foot Wounds

NCT01056198
View directory record Official record
Conditions
Diabetic Foot Ulcers, Foot Wounds
Interventions
Santyl, Control
Drug · Procedure
Lead sponsor
Healthpoint
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
9
States / cities
Phoenix, Arizona • Lincoln, Nebraska • Altoona, Pennsylvania + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2012 · Synced Sep 17, 2026, 5:36 PM EDT